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ABSTRACT
Objective Patients with chronic obstructive pulmonary
disease (COPD) have increased mortality following
myocardial infarction (MI) compared with patients
without COPD. We investigated the extent to which
differences in recognition and management after MI could
explain the mortality difference.
Methods 300 161 patients with a ﬁrst MI between
2003 and 2013 were identiﬁed in the UK Myocardial
Ischaemia National Audit Project database. Logistic
regression was used to compare mortality in hospital and
at 180 days postdischarge between patients with and
without COPD. Variables relating to inhospital factors
(delay in diagnosis, use of reperfusion and time to
reperfusion/use of angiography) and use of secondary
prevention were sequentially added to models.
Results Mortality was higher for patients with COPD
both inhospital (4.6% vs 3.2%) and at 180 days (12.8%
vs 7.7%). After adjusting for inhospital factors, the effect
of COPD on inhospital mortality after MI was reduced for
both ST-elevation myocardial infarctions (STEMIs) and
non-STEMIs (STEMIs OR 1.24 (95% CI 1.10 to 1.41) to
1.13 (95% CI 0.99 to 1.29); non-STEMIs OR 1.34 (95%
CI 1.24 to 1.45) to 1.16 (95% CI 1.07 to 1.26)).
Adjusting for inhospital factors reduced the effect of
COPD on mortality after non-STEMI at 180 days (OR 1.56
(95% CI 1.47 to 1.65) to 1.37 (95% CI 1.31 to 1.44)).
Adjusting for use of secondary prevention also reduced
the effect of COPD on mortality at 180 days for STEMIs
and non-STEMIs (STEMIs OR 1.45 (95% CI 1.31 to 1.61)
to 1.25 (95% CI 1.11 to 1.41); non-STEMIs OR 1.37
(95% CI 1.31 to 1.44) to 1.26 (95% CI 1.17 to 1.35).
Conclusions Delayed diagnosis, timing and use of
reperfusion of a STEMI, use of angiography after a non-
STEMI and use of secondary prevention medicines are all
potential explanations for the mortality gap after MI in
people with COPD.
INTRODUCTION
People with chronic obstructive pulmonary disease
(COPD) are at higher risk of cardiovascular
disease1 2 and are known to have poorer medium
and longer-term outcomes after myocardial infarc-
tion (MI) compared with people without COPD,
however, ﬁndings for inhospital mortality have
been mixed.3–6 The heterogeneity in ﬁndings on
inhospital mortality may be due to differences in
treatment practices. COPD is currently the third
leading cause of death worldwide.7 As up to
one-third of deaths in people with COPD are due
to cardiovascular disease,8 reducing deaths after MI
in this population is important. In addition, there is
a lack of evidence for the effectiveness of treat-
ments in those with comorbidities.
Recent years have seen improvements in out-
comes for patients after MI.9 However, several
recent studies have continued to report poorer
mortality for patients with COPD after an MI.
Although the reasons for increased mortality after
MI in patients with COPD are likely to include
biological factors related to COPD, differences in
recognition and management between patients
with and without COPD may play a role. Recent
work has demonstrated that patients with COPD
are less likely to receive reperfusion treatment or
β blockers after an MI,10 and that not prescribing β
blockers to patients with COPD impacts on
mortality.11
Little is known about potential differences in
prescribing of other secondary prevention medi-
cines, inhospital treatment or on the effects that
any differences in these potentially modiﬁable
factors may have on mortality.
We used Myocardial Ischaemia National Audit
Project (MINAP), a national register of hospital
care for acute coronary syndromes (ACS), to inves-
tigate the extent to which differences in recognition
and management of an MI might account for the
mortality gap in patients with COPD at the popula-
tion level.
METHODS
Data source
The MINAP database is a registry of all admissions
for MI and other ACS to hospitals in the UK. The
dataset includes information on patient demograph-
ics, comorbidities, drugs on admission, initial diag-
nosis, ﬁnal diagnosis, inhospital drug treatment,
timing of reperfusion therapies, inhospital outcome
and drugs given on discharge.12
We included all patients with a ﬁrst diagnosis of
ST-elevation myocardial infarction (STEMI) from
January 2003 to June 2013 or non-ST-elevation
myocardial infarction (non-STEMI) from January
2004 to December 2012. Records were excluded if
they did not have a patient unique identiﬁer, if
patients had missing values for presence of
obstructive airway disease or smoking history or if
Ofﬁce of National Statistics (ONS) mortality data
were missing.
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Exposure identiﬁcation
The obstructive airway disease variable in MINAP does not dif-
ferentiate between COPD and asthma. In order to identify
patients with COPD for this analysis, a strategy was
developed and tested in a subset of the data linked with data
from the Clinical Practice Research Datalink (CPRD). CPRD is
a large UK clinical database of primary care medical records
which includes over 5.5 million active patients (8% of the
population).13 Around half of the CPRD records have been
linked to the MINAP database through the CALIBER linkage
scheme.14 Patients with COPD can be identiﬁed in CPRD
through the use of validated diagnostic codes. Using this subset
of linked data, we developed strategy for identifying COPD
patients in MINAP using CPRD-identiﬁed COPD as a reference
standard. In this subset of data, patients with COPD were iden-
tiﬁed using a combination of MINAP-recorded obstructive
airway disease and a smoking history (ex or current smoker).
This strategy resulted in adequate identiﬁcation of patients with
COPD in MINAP, with agreement of 90.9%.
Outcome deﬁnitions
Recognition and management
Delay in diagnosis of MI, reperfusion after a STEMI, use of
angiography in hospital after a non-STEMI and discharge on
secondary prevention drugs were investigated. Two deﬁnitions
of delay in diagnosis were investigated for patients with a ﬁnal
diagnosis of STEMI: (1) delay in diagnosis of deﬁnite STEMI
(deﬁned as those who did not have an initial diagnosis of deﬁn-
ite STEMI) and (2) delay in diagnosis of ACS (deﬁned as those
whose initial diagnosis was not STEMI, probable MI or ACS).
For those patients with a ﬁnal diagnosis of non-STEMI, one def-
inition for delay in diagnosis was investigated: delay in diagnosis
of ACS (deﬁned as those whose initial diagnosis was not
STEMI, probable MI or ACS).
Mortality outcomes
The UK ONS collects data on all recorded deaths in England
and Wales. MINAP is linked with ONS mortality data, which
provides data on vital status at 180 days postdischarge.
Mortality at 180 days postdischarge was assessed for those who
survived until discharge.
Statistical analysis
Demographic and clinical characteristics were tabulated for
patients with COPD and non-COPD patients. All analyses were
stratiﬁed by type of MI (STEMI or non-STEMI). The models
were adjusted for smoking status, age, sex and calendar year,
comorbidities including prior angina, cerebrovascular disease,
chronic kidney failure, diabetes, congestive heart failure, hyper-
tension, hyperlipidaemia, peripheral vascular disease, previous
percutaneous coronary intervention (PCI) and previous coron-
ary artery bypass graft and cardiovascular drugs (ACE inhibitor
or angiotensin receptor blocker, β blocker, statin and thienopyri-
dine) use on admission. Following the suggested practice for
missing data in MINAP,15 missing values for comorbidities and
drugs on admission were recoded to ‘no’. Other variables were
not recoded and analyses were conducted on the basis of com-
plete case analysis. Data were analysed using Stata V.13.0.
Analysis was conducted in three parts:
1. Describing the problem: differences in mortality after MI
between patients with COPD and non-COPD patients
We compared crude proportions of patients with COPD dying
inhospital and at 180 days postdischarge to patients without
COPD. We then used logistic regression to adjust the compari-
sons of mortality for possible confounders for age, sex, smoking
status, calendar year, comorbidities and drugs used on arrival.
2. Possible inhospital explanations: differences in recognition
and management after an MI between patients with COPD
and non-COPD patients
For STEMIs, we investigated differences in delay in STEMI
diagnosis, use of primary PCI (pPCI), use of thrombolysis, time
to reperfusion from hospital admission and use of secondary
prevention drugs on discharge. We investigated the impact of
delay in diagnosis on time to reperfusion, and we assessed
whether COPD modiﬁed this relationship. For non-STEMIs, we
investigated delay in diagnosis of MI, use of angiography in hos-
pital and use of secondary prevention drugs on discharge.
3. Accounting for differences in mortality after MI between
patients with COPD and non-COPD patients in terms of
hospital processes
In order to investigate to what extent differences in diagnosis
and treatment of patients with COPD after an MI might
account for differences in mortality, variables relating to inhos-
pital processes investigated in (2) were sequentially added to
mortality models created in (1) with reference to a directed
acyclic graph (see online supplementary material). Attributable
risk of death due to COPD following MI was calculated before
and after adjustment for inhospital processes using the formula
(OR-1)/OR×100.
RESULTS
Characteristics of participants
Of the 300 146 patients with ﬁrst MI identiﬁed over the period,
34 027 (11.3%) had COPD. The inclusion and exclusion of
records in the MINAP database are detailed in ﬁgure 1. The
characteristics of the patients included in the study are detailed
in table 1. Mortality was higher for patients with COPD both
inhospital (4.6% vs 3.2%) and at 180 days (12.8% vs 7.7%).
ST-elevation myocardial infarctions
1. Describing the problem: differences in mortality after MI
between patients with COPD and non-COPD patients
After adjusting for age, sex, smoking status, calendar year,
comorbidities and drugs on arrival, mortality in patients with
COPD was higher than non-COPD patients in hospital (OR
1.24, 95% CI 1.10 to 1.41), and 180 days after discharge (OR
1.45, 95% CI 1.33 to 1.59).
2. Possible inhospital explanations: differences in recognition
and management after an MI between patients with COPD
and non-COPD patients
Differences in diagnosis and inhospital recognition management
are presented in table 2. Patients with COPD who had a STEMI
were more likely to have an initial diagnosis other than deﬁnite
STEMI (OR 1.24, 95% CI 1.19 to 1.30) or ACS (OR 1.52,
95% CI 1.42 to 1.62). After a STEMI, patients with COPD
were less likely to have pPCI (OR 0.87, 95% CI 0.83 to 0.92).
There was no evidence that patients with COPD were less likely
to receive thrombolysis (OR 0.96, 95% CI 0.91 to 1.10).
In adjusted results, differences in time to reperfusion have
been expressed in terms of exponentiated linear regression coef-
ﬁcients which, in this case, represent ratios of geometric means.
The relationship between COPD and time to reperfusion was
found to be different depending on whether diagnosis of MI
was delayed (p value for interaction <0.001). The median time
to reperfusion was 43.7 min longer for patients with COPD
compared with non-COPD patients among those who had a
delay in diagnosis (median time to reperfusion 152.9 min (IQR,
2 Rothnie KJ, et al. Heart 2015;0:1–8. doi:10.1136/heartjnl-2014-307251
Special populations
group.bmj.com on March 25, 2015 - Published by http://heart.bmj.com/Downloaded from 
74.3–705.6 min) for patients with COPD, and 109.2 min (IQR,
50.2–260.0 min) for non-COPD patients). This difference
remained on adjusted analysis and corresponded to 47% (95%
CI 15% to 88%) longer time to reperfusion for patients with
COPD with delayed diagnosis of MI, compared with
non-COPD patients with delayed diagnosis of MI. There was no
difference in time to reperfusion between patients with COPD
and non-COPD patients among those without a delay in diagno-
sis (see details in online supplementary appendix). Patients with
COPD were less likely to receive any of the secondary preven-
tion drugs, apart from thienopyridines, on discharge compared
with non-COPD patients, β blockers signiﬁcantly more so than
other drugs (OR 0.26 (95% CI 0.25 to 0.27)).
3. Accounting for differences in mortality after MI between
patients with COPD and non-COPD patients in terms of
hospital processes
When compared with the result found in (1), inhospital mortal-
ity was reduced after adjusting separately for both diagnostic
delay (OR 1.20 (95% CI 1.06 to 1.36)) and time to reperfusion
and use of pPCI (OR 1.11 (95% CI 0.94 to 1.31; table 3)).
After adjusting for all inhospital factors, the OR for mortality
was 1.13 (95% CI 0.99 to 1.29). For mortality at 180 days, the
OR was 1.45 (95% CI 1.33 to 1.59) after adjusting for age, sex,
smoking, calendar year, drugs used on admission and comorbid-
ities, and was 1.45 (95% CI 1.31 to 1.61) after additionally
adjusting for diagnostic delay, use of pPCI and time to reperfu-
sion. Adjusting for use of secondary prevention drugs on dis-
charge substantially reduced ORs for 180 day mortality
compared with models only adjusting for inhospital factors
(OR 1.25 (95% CI 1.11 to 1.41)).
After adjusting for inhospital processes, the estimated attribut-
able risk of inhospital death following a STEMI due to COPD
in patients with COPD decreased from 19.4% (95% CI 9.1% to
29.1%) to 11.5% (95% CI −1.0% to 22.4%). After adjusting
for inhospital processes, the estimated attributable risk for death
at 180 days due to COPD in patients with COPD following a
STEMI decreased from 31.0% (95% CI 24.8% to 37.1%) to
20.0% (95% CI 9.9% to 29.1%).
Non-ST-elevation myocardial infarctions
1. Describing the problem: differences in mortality after MI
between patients with COPD and non-COPD patients
After adjusting for age, sex, smoking status, calendar year,
comorbidities and drugs on arrival, mortality in patients
with COPD was higher than non-COPD patients in hospital
(OR 1.34 (95% CI 1.24 to 1.45)) and 180 days after discharge
(OR 1.56 (95% CI 1.47 to 1.65)).
2. Possible inhospital mechanisms: differences in diagnosis and
management after an MI between patients with COPD and
non-COPD patients
Results from the comparison of treatment and diagnosis after a
non-STEMI are presented in table 4. Patients with COPD
were more likely to have an initial diagnosis other than ACS
after a non-STEMI (OR 1.46 (95% CI 1.41 to 1.50)). After a
non-STEMI, patients with COPD were less likely to receive
angiography in hospital (OR 0.69 (95% CI 0.66 to 0.71)).
Figure 1 Study selection.
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Patients with COPD were less likely to receive any of the sec-
ondary prevention drugs on discharge, apart from thienopyri-
dines, compared with non-COPD patients, β blockers
signiﬁcantly more so than other secondary prevention drugs
(OR 0.25 (95% CI 0.24 to 0.25)).
3. Accounting for differences in mortality after MI between
patients with COPD and non-COPD patients in terms of
hospital processes
When compared with results found in (1), inhospital mortality
was reduced after adjusting separately for both delay in diagno-
sis (OR 1.29 (95% CI 1.19 to 1.39)) and use of angiography
(OR 1.18 (95% CI 1.09 to 1.29); table 5)). After adjusting for
both delay in diagnosis and use of angiography the OR for
inhospital mortality was 1.16 (95% CI 1.07 to 1.26). Inhospital
factors also appeared to explain some of the mortality differ-
ence after a non-STEMI at 180 days. For mortality at 180 days,
the OR was reduced from 1.56 (95% CI 1.47 to 1.65) to 1.37
(95% CI 1.31 to 1.44). Use of secondary prevention also
seemed to explain some of the gap in mortality at 180 days.
Compared with the model which only adjusted for inhospital
processes, the OR for mortality at 180 days was reduced from
1.37 (95% CI 1.31 to 1.44) to 1.26 (95% CI 1.17 to 1.35).
After adjusting for inhospital processes, the estimated attribut-
able risk for inhospital death following a non-STEMI due to
COPD in patients with COPD decreased from 25.4% (95% CI
19.4% to 31.0%) to 13.8% (95% CI 6.5% to 21.6%). After
adjusting for inhospital processes, the estimated attributable
risk for death at 180-days due to COPD in patients with COPD
following a non-STEMI decreased from 35.9% (95% CI 32.0%
to 39.4%) to 20.6% (95% CI 14.5% to 25.9%).
DISCUSSION
Summary of main ﬁndings
For STEMIs, some of the in inhospital mortality difference
between patients with COPD and non-COPD patients may be
attributable to delays in diagnosis and use of and increased time to
Table 1 Characteristics of patients in the study
Characteristic COPD n (%) Non-COPD n (%)
Sex
Male 21 053 (61.9) 178 611 (67.1)
Female 12 908 (37.9) 86 504 (32.5)
Missing 80 (0.2) 956 (0.36)
Age (years)
<60 7627 (22.6) 90 557 (34.1)
60–70 8830 (26.0) 62 947 (23.7)
71–80 10 622 (31.3) 61 549 (23.2)
>80 6786 (20.0) 50 126 (18.9)
Missing 0 0
Smoking status
Current 14 666 (43.2) 90 026 (34.0)
Ex 19 244 (56.8) 87 612 (33.0)
Never 0 87 541 (33.0)
Missing 0 0
Previous Angina
Yes 7426 (21.8) 41 417 (15.6)
No 25 936 (76.2) 223 089 (83.9)
Missing 679 (2.0) 1565 (0.6)
Previous PCI
Yes 908 (2.7) 6622 (2.5)
No 32 082 (94.3) 255 449 (96.0)
Missing 1051 (3.1) 3916 (1.5)
Previous CABG
Yes 786 (2.3) 5704 (2.1)
No 32 227 (94.7) 256 574 (96.4)
Missing 1028 (3.0) 3793 (1.4)
Diabetes
Yes—diet controlled 1193 (3.5) 8322 (3.1)
Yes—oral 2902 (8.5) 21 418 (8.1)
Yes—insulin 1241 (3.7) 8986 (3.4)
Yes—insulin and oral 176 (0.5) 1178 (0.4)
No 28 030 (82.3) 223 040 (83.8)
Missing 499 (1.5) 3127 (1.2)
Treated for hypertension
Yes 15 304 (45.0) 117 886 (44.3)
No 18 151 (53.3) 146 459 (55.1)
Missing 586 (1.7) 1726 (0.7)
Treated for hyperlipidaemia
Yes 9091 (26.7) 73 641 (27.7)
No 23 399 (68.7) 185 043 (69.6)
Missing 1551 (4.6) 7387 (2.8)
Peripheral vascular disease
Yes 1962 (5.8) 9061 (3.4)
No 30 872 (90.7) 253 720 (95.4)
Missing 1207 (3.6) 3290 (1.2)
Previous cerebrovascular disease
Yes 2823 (8.3) 16 829 (6.3)
No 30 354 (89.2) 247 418 (93.0)
Missing 864 (2.5) 1824 (0.7)
Heart failure
Yes 2037 (6.0) 7426 (2.8)
No 31 080 (91.3) 256 677 (96.5)
Missing 924 (2.71) 1968 (0.7)
Renal failure
Yes 1681 (4.9) 8428 (3.2)
No 31 452 (92.4) 255 732 (96.1)
Missing 908 (2.7) 1911 (0.7)
Continued
Table 1 Continued
Characteristic COPD n (%) Non-COPD n (%)
β blocker on arrival
Yes 3016 (8.9) 44 585 (16.8)
No 23 544 (69.1) 162 876 (61.2)
Missing 7481 (22.0) 58 610 (22.0)
ACEi/ARB on arrival
Yes 8228 (24.2) 57 288 (21.53)
No 18 331 (53.9) 150 036 (56.4)
Missing 7482 (22.0) 58 747 (22.1)
Statin on arrival
Yes 9446 (27.8) 65 062 (24.5)
No 17 409 (51.1) 144 498 (54.3)
Missing 7186 (21.1) 56 511 (21.2)
Thienopyridine on arrival
Yes 2948 (8.7) 23 240 (8.7)
No 22 729 (66.8) 176 548 (66.4)
Missing 8364 (24.6) 66 283 (24.9)
Death in hospital 1561 (4.6) 8574 (3.2)
Death at 180 days
(survivors to discharge)
4166 (12.8) 19 693 (7.7)
ACEi, ACE inhibitor; ARB, angiotensin receptor blocker; CABG, coronary artery bypass
graft; COPD, chronic obstructive pulmonary disease; PCI, percutaneous coronary
intervention.
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reperfusion. Some of the increased mortality for STEMIs at longer
time periods up to 6 months may be attributable to decreased use
of secondary prevention medicines, especially β blockers, but not
inhospital processes. For non-STEMIs, some of the difference in
inhospital mortality may be attributable to delays in diagnosis and
decreased use of angiography shortly after MI. Some of the
increased mortality for non-STEMIs at longer time periods up to
6 months may be attributable to decreased use of secondary pre-
vention medicines, and to inhospital delays in diagnosis and
decreased use of angiography in hospital.
Interpretation and comparison with other studies
Several studies have shown both the increased risk for death
following MI for people with COPD and differences in manage-
ment. These studies speciﬁcally showed reduced use of second-
ary prevention and pPCI after a STEMI in patients with
COPD,5 10 16–18 these ﬁndings have been replicated here. This
study has also shown that these differences in treatment are pos-
sible explanations for some of the mortality gap at the
population level for both STEMIs and non-STEMIs. In particu-
lar, we were able to make use of the detailed timing variables
available in MINAP to investigate differences in time to reperfu-
sion after a STEMI.
For STEMIs, we found that diagnosis of MI is more likely to
be delayed for patients with COPD compared with non-COPD
patients, and that time to reperfusion is longer after a STEMI.
We also showed that the effect of delay in diagnosis of MI on
the time to reperfusion was greater in patients with COPD com-
pared with non-COPD patients. Patients with COPD were more
likely to have a delay in diagnosis and the effect of this delay in
diagnosis in time to reperfusion was more severe for them than
non-COPD patients. The reason for the delay in diagnosis of
MI in patients with COPD may be because symptoms of MI in
patients with COPD may be incorrectly attributed to their
COPD rather than an MI.
We found that after a non-STEMI, patients with COPD were
less likely to receive angiography in hospital than non-COPD
patients, and this explained some of the excess inhospital and
Table 2 Differences in recognition and treatment of STEMIs between patients with COPD and non-COPD patients
Inhospital treatment and diagnosis
COPD
N (%)
Non-COPD
N (%)
Unadjusted OR
(95% CI)
Minimally adjusted
OR (95% CI)* Adjusted OR (95% CI)†
Initial diagnosis other than definite
STEMI (for final diagnosis is STEMI)
3080 (23.9) 24 752 (19.9) 1.26 (1.21 to 1.32) 1.28 (1.23 to 1.34) 1.24 (1.19 to 1.30)
Initial diagnosis other than ACS 1186 (9.2) 7398 (6.0) 1.59 (1.50 to 1.71) 1.68 (1.64 to 1.73) 1.52 (1.42 to 1.62)
Primary PCI 4108 (31.8) 44 177 (35.6) 0.84 (0.81 to 1.87) 0.69 (0.67 to 0.71) 0.87 (0.83 to 0.92)
Thrombolysis 5449 (42.6) 52 414 (42.7) 0.99 (0.96 to 1.03) 1.00 (0.96 to 1.03) 0.96 (0.91 to 1.10)
Time to reperfusion
COPD
Minutes
(median IQR)
Non-COPD
Minutes
(median IQR)
Unadjusted
exponentiated
regression coefficient
(95% CI)
Minimally adjusted
exponentiated regression
coefficient (95% CI)*
Adjusted
exponentiated
regression coefficient
(95% CI)†
Time to reperfusion from admission
(overall)
37.1 (21.8–67.7) 35.0 (21.8–63.4) 1.07 (1.04 to 1.09) 1.05 (1.03 to 1.07) 1.04 (1.02 to 1.07)
Time to reperfusion from admission
(initial diagnosis other than STEMI)
152.9 (74.3–705.6) 109.2 (50.2–260.0) 1.44 (1.24 to 1.67) 1.35 (1.16 to 1.58) 1.47 (1.15 to 1.88)
Time to reperfusion from admission
(initial diagnosis STEMI)
35.0 (21.8–63.4) 35.0 (21.8–61.2) 1.04 (1.01 to 1.06) 1.03 (1.01 to 1.05) 1.03 (1.00 to 1.05)
Discharge treatment COPD n (%) Non-COPD n (%)
Unadjusted
OR (95% CI)
Minimally adjusted
OR* (95% CI)
Adjusted
OR (95% CI)†
Discharge on β blockers 5776 (44.7) 94 784 (76.4) 0.25 (0.24 to 0.26) 0.25 (0.24 to 0.26) 0.26 (0.25 to 0.27)
Discharge on ACE inhibitor or
angiotensin receptor blocker
9579 (74.2) 96 508 (77.8) 0.83 (0.79 to 0.86) 0.87 (0.83 to 0.91) 0.89 (0.85 to 0.93)
Discharge on aspirin 10 344 (80.1) 102 925 (82.9) 0.83 (0.79 to 0.87) 0.87 (0.83 to 0.92) 0.90 (0.85 to 0.94)
Discharge on statin 10 373 (80.4) 102 785 (82.8) 0.85 (0.81 to 0.89) 0.88 (0.84 to 0.93) 0.91 (0.86 to 0.95)
Discharge on thienopyridine 7799 (60.4) 77 543 (62.5) 0.91 (0.88 to 0.95) 0.96 (0.92 to 1.01) 0.98 (0.94 to 1.03)
*Adjusted for age, sex smoking status and calendar year.
†Adjusted for age, sex, smoking status, calendar year, drugs on admission and comorbidities.
ACS, acute coronary syndromes; COPD, chronic obstructive pulmonary disease; STEMI, ST-elevation myocardial infarction.
Table 3 Mortality after STEMI
Adjusted for age,
sex, smoking
status and year
Adjusted for
model 1 variables
and comorbidities
and drugs on arrival
Adjusted for models 1
and 2 variables
and diagnostic delay
Adjusted for models 1
and 2 variables and use
of reperfusion and
time to reperfusion
Adjusted for
models 1–4
Adjusted for
models 1–4
variables and
secondary
prevention
Model 1 Model 2 Model 3 Model 4 Model 5 Model 6
OR (95% CI)
Inhospital mortality 1.27 (1.16 to 1.39) 1.24 (1.10 to 1.41) 1.20 (1.06 to 1.36) 1.11 (0.94 to 1.31) 1.13 (0.99 to 1.29) –
180-day mortality 1.43 (1.29 to 1.58) 1.45 (1.33 to 1.59) 1.43 (1.32 to 1.54) 1.46 (1.32 to 1.62) 1.45 (1.31 to 1.61) 1.25 (1.11 to 1.41)
All Odds ratios compare patients with COPD with non-COPD patients.
COPD, chronic obstructive pulmonary disease; STEMI, ST-elevation myocardial infarction.
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180-day mortality. Use of angiography is driven by risk scoring,
and patients at moderate and higher risk of death within
6 months should be offered angiography within 96 h of admis-
sion to hospital after a non-STEMI.19 It is unclear why, as a
population, that although patients with COPD are at a higher
risk of mortality they are less likely to receive angiography in
hospital.
After both STEMIs and non-STEMIs, patients with COPD
were less likely to be prescribed secondary prevention medicines
than non-COPD patients. This may only have been to a clinically
relevant degree for β blockers. It is known that patients with
COPD are less likely to be prescribed β blockers after an MI, and
that prescribing them improves survival.11 This study has demon-
strated that the increased mortality associated with not prescrib-
ing secondary prevention medicines could explain some of the
mortality gap up to 6 months at the population level.
We found that recognition of MI in patients with COPD was
impaired compared with non-COPD patients. However, all
patients included in this analysis were eventually diagnosed
with MI. This suggests that patients with COPD may be at
higher risk of having a completely missed MI. Indeed, recent
work has suggested that as many as 1 in 12 patients admitted
to hospital with an exacerbation of COPD meet the criteria for
MI, and that this represents underdiagnosis of MI in patients
with COPD.20 However, as troponin may also be increased
during stable periods of COPD,21 there is also a potential for
overdiagnosis of MI in people with COPD. Any future inter-
vention which aims to increase recognition of MI in people
with COPD should also investigate the potential effects of
overdiagnosis.
Strengths and limitations
The major strengths of this study were its size, representative-
ness and level of detail on inhospital management and
outcomes. The study included over 300 000 people and used
data collected from all hospitals in the UK which admit patients
for ACS. As secondary prevention treatment is known to be dif-
ferent for patients with COPD compared with non-COPD
patients, only using ﬁrst MIs allowed us to assess the effect of
COPD on mortality after an MI without bias due to differences
in previous treatment. Another strength of this study was our
ability to separate factors which could explain increased inhospi-
tal mortality from increased mortality following discharge. If
patients with COPD were more likely to die in hospital, as we
found, the reasons that they did not receive certain treatments
may have been because they were more likely to die before they
received these treatments compared with non-COPD patients.
In order to avoid this bias, for mortality at 180 days, we only
analysed data for those who had survived until at least dis-
charge. This also allowed the potential contribution of second-
ary prevention to the mortality gap to be investigated.
One of the limitations of this study is potential misclassiﬁca-
tion of COPD status. The strategy used to identify may have
misclassiﬁed asthmatic smokers as patients with COPD, and may
have misclassiﬁed patients with COPD as non-COPD patients.
However, the prevalence of COPD in our study is similar to
that of previous work in similar settings.5 10 16 22 The presence
of asthmatics in our COPD group and patients with COPD in
the non-COPD group is likely to have biased our ﬁndings
towards the null. However, this would not change our ﬁndings.
In addition, a sensitivity analysis, which compared mortality for
asthmatic patients compared with non-asthmatic patients found
that mortality was not increased in the asthmatic group
(see online supplementary material). One of the limitations of
using an audit database such as MINAP is the lack of available
data which would not have been collected at hospital admission.
Ideally, information on COPD severity and cause of death
would have been collected. In addition, ideally information on
Table 4 Differences in recognition and inhospital treatment of non-STEMIs between patients with COPD and non-COPD patients
COPD
N (%)
Non-COPD
N (%)
Unadjusted
OR (95% CI)
Minimally adjusted
OR* (95% CI)
Adjusted OR
(95% CI)†
Inhospital treatment and diagnosis
Initial diagnosis other than MI 9551 (45.2) 50 365 (35.5) 1.50 (1.46 to 1.54) 1.68 (1.64 to 1.73) 1.46 (1.41 to 1.50)
Angiography in hospital 8629 (40.9) 74 304 (52.2) 0.77 (0.76 to 0.79) 0.63 (0.61 to 0.65) 0.69 (0.66 to 0.71)
Discharge treatment
Discharge on βblockers 6632 (31.4) 925 059 (64.9) 0.25 (0.24 to 0.26) 0.24 (0.23 to 0.25) 0.25 (0.24 to 0.25)
Discharge on ACE inhibitor
or angiotensin receptor blocker
12 762 (60.4) 89 368 (63.0) 0.90 (0.87 to 0.92) 0.91 (0.88 to 0.94) 0.94 (0.91 to 0.97)
Discharge on aspirin 15 234 (72.1) 106 652 (75.1) 0.86 (0.83 to 0.88) 0.88 (0.85 to 0.91) 0.91 (0.88 to 0.94)
Discharge on statin 15 141 (71.7) 104 804 (73.8) 0.90 (0.87 to 0.93) 0.90 (0.87 to 0.93) 0.93 (0.90 to 0.96)
Discharge on thienopyridine 11 277 (53.4) 78 233 (55.1) 0.93 (0.90 to 0.96) 0.95 (0.91 to 0.98) 0.97 (0.94 to 1.01)
*Adjusted for age, sex smoking status and calendar year.†Adjusted for age, sex, smoking status, calendar year, drugs on admission and co-morbidities.
COPD, chronic obstructive pulmonary disease; MI, myocardial infarction; STEMI, ST-elevation myocardial infarction.
Table 5 Mortality after non-STEMI. All ORs compare patients with COPD with non-COPD patients
Adjusted for age,
sex, smoking status
and year
Adjusted for model 1
variables and
comorbidities and
drugs on arrival
Adjusted for models
1 and 2 variables
and diagnostic
delay
Adjusted for models
1 and 2 variables
and use of
angiography in
hospital
Adjusted for
models 1–4
variables
Adjusted for models
1–4 variables and
secondary
prevention
Model 1 Model 2 Model 3 Model 4 Model 5 Model 6
OR (95% CI)
Inhospital mortality 1.40 (1.30 to 1.52) 1.34 (1.24 to 1.45) 1.29 (1.19 to 1.39) 1.18 (1.09 to 1.29) 1.16 (1.07 to 1.26) –
180-day mortality 1.63 (1.56 to 1.70) 1.56 (1.47 to 1.65) 1.45 (1.38 to 1.52) 1.43 (1.34 to 1.50) 1.37 (1.31 to 1.44) 1.26 (1.17 to 1.35)
COPD, chronic obstructive pulmonary disease; STEMI, ST-elevation myocardial infarction.
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socioeconomic status would have been available as this is a
potential confounder for the relationship between COPD and
mortality after MI. Future studies should investigate the rela-
tionship between COPD severity and explanations for the mor-
tality gap in patients with COPD after MI and cause of death in
patients with COPD following MI.
Conclusions
Patients with COPD appear to receive poorer treatment after an
MI compared with non-COPD patients. These differences in
recognition and treatment of MI seem to explain some of the
mortality gap between patients with COPD and non-COPD
patients both inhospital and at 6 months postdischarge. Delayed
diagnosis, timing and use of reperfusion of a STEMI, use of
angiography after a non-STEMI and use of secondary preven-
tion medicines are all potential explanations for the mortality
gap after MI in people with COPD.
Key messages
What is already known on this subject?
People with chronic obstructive pulmonary disease (COPD) have
both a higher risk for myocardial infarction (MI) and poorer
long-term outcomes following MI. Previous studies have also
shown that patients with COPD are less likely to receive β
blockers on discharge after an MI and are less likely to receive
PCI after an ST-elevation myocardial infarction (STEMI). Findings
for differences in inhospital mortality have been mixed, with
some studies ﬁnding higher mortality for patients with COPD and
some studies ﬁnding no difference. The heterogeneity in ﬁndings
may be due to differences in treatment practices. The extent to
which differences in treatment can explain differences in
mortality at the population level, the ‘mortality gap’, is unclear.
What might this study add?
This study aimed to determine whether differences in inhospital
treatment and discharge between patients with and without
COPD could explain all or some of the difference in mortality for
both inhospital and at 180 days postdischarge at the population
level. We found that delayed diagnosis of MI, decreased use of
reperfusion and increased time to reperfusion after a STEMI,
decreased use of angiography after a non-STEMI and decreased
use of secondary prevention medicines might all explain some
of the mortality gap for people with COPD after an MI.
How might this impact on clinical practice?
We have found that differences in potentially modiﬁable
inhospital processes may explain some of the mortality gap
between patients with and without COPD after an MI. Clinicians
need to be aware that it may be easier to miss MIs in people
with COPD and may need to be aware of more unusual
presentations of MI in people with COPD. In addition, our
results suggest that patients with COPD may beneﬁt from more
aggressive treatment after an MI.
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